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Table 1. The outcome of locking tunneled hemodialysis catheters with cefotaxime and heparin in terms of ceatheter thrombosis, CRBSI
incidence, and CRBSI-related mortality (July 2002–June 2003)
Control group (N = 19) Study group (N = 67)
Tunneled HD (heparin alone, 6935 (cefotaxime + heparin, 24,455 Relative-risk reduction (%),
catheter events catheter days) N, total, % catheter days)a N, total, % 95% CI, P value
Catheter thromboses 6/19 (31.5) 9/67 (13.4) 57.3%, 1.340-4.701, 0.003
CRBSI episodes 17/19 (2.45/1000 catheter-days) 14/67 (0.57/1000 catheter-days) 76.7%, 3.086-6.430, < 0.0001
CRBSI-related mortality 5/19 (31.6) 7/67 (10.4) 67.1%, 1.517-5.864, < 0.001
95% CI, 95% confidence interval; CRBSI, catheter-related blood-stream infections.
aCefotaxime-heparin ‘lock’ solution composition, cefotaxime 10 mg/mL, heparin 5000 U/mL (to fill 1.3 mL in venous and 1.2 mL in arterial lumen of the catheter
with combined volume of approximately 2.5 mL containing total of 25 mg of cefotaxime).
observed in ‘locked’ group compared with control group
(Table 1).
Thus, locking HD catheters with cefotaxime may
evenly reduce the risk of development of CRBSI besides
minimizing the odds of aminoglycoside-associated oto-
toxicity.
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The differential impact of risk
factors on mortality in
hemodialysis and peritoneal
dialysis
To the Editor: In the article by Vonesh et al [1], dis-
crepancies in survival on different treatment modalities
for different patient groups is described in a large cohort
of patients. Although a considerable number of comor-
bidity conditions were included for this variable, I feel
that a major variable (i.e., the failed transplant recipi-
ent returning to dialysis) should have been included, or
preferably should have been added as a separate risk fac-
tor for mortality in dialysis patients.
These patients are at high risk for premature death,
excluding death within the first 90 days after starting
dialysis, especially when they continue even low dose im-
munosuppressive medication during dialysis [2, 3]. Fur-
thermore, these patients generally start on hemodialysis
during the first period after transplant failure (i.e., the first
year after graft failure). This would negatively influence
the outcome for this treatment modality as compared to
peritoneal dialysis with regard to mortality, and would,
therefore, be another plausible explanation for the high
initial mortality associated with hemodialysis found in
this study.
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Prevention of renal cell
carcinoma from hemodialysis
patients by regulating
epigenetic factors
To the Editor: Long duration of patients on hemodialy-
sis induces an increased incidence of renal cell carcinoma
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(RCC) compared with the general population. We have
reported that connexin (Cx) 32, a member of gap junc-
tion, acts as a potential tumor suppressor gene in the RCC
with tissue specificity [1], and that loss of function of the
Cx gene during hemodialysis is caused by hypermethyla-
tion of CpG island in promoter region of the Cx gene, but
not mutation/deletion of the Cx gene [2]. Thus, if the epi-
genetic inactivation of Cx32 should be abrogated by phar-
macologic treatment without any toxicity, the treatment
may lead to establishment of a new preventive procedure
against the RCC from hemodialysis patients.
Of agents to release epigenetic inactivation of tumor
suppressor genes, zebularine, a cytidine analogue con-
taining a 2-(1H)-pyrimidinone, possesses some proper-
ties desirable for a therapeutic agent because the agent
is very stable and has an extremely low toxicity, unlike
a representative DNA demethylating agent, 5-Aza-2′-
deoxycytidine [3]. We have recently demonstrated that
DNA demethylation by 5-Aza-2′-deoxycytidine restores
the expression of Cx32, and reinduces tumor-suppressive
effect of the Cx gene against RCC [4]. Additionally,
we have confirmed that, of silenced tumor suppressor
genes, zebularine specifically up-regulates Cx32 gene in
the RCC through DNA demethylation, and that the re-
expression is closely associated with negative growth con-
trol of the RCC. These results suggest that zebularine
is an effective agent to specifically restore the tumor-
suppressive effect of Cx32 in kidney, and to establish a
new preventive strategy against the RCC from hemodial-
ysis patients with low toxicity.
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